News Detail
Maryland, 19 Dec 2017: The U.S. Food and Drug Administration (FDA) is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) concerning gadolinium remaining in patients’ bodies, including......
View Details
Source : US FDA Safety Anouncement
Related News
- Fake PPE products under label of KARAM Industries seized in Delhi (23-09-2020)
- Bayer's Aflibercept injection gets DCGI nod for Diabetic Macular Edema indication (23-09-2020)
- Kerala to have one of the first medical device parks (23-09-2020)
- India's Serum Institute starts manufacturing Codagenix's potential Covid-19 vaccine (23-09-2020)
- Madras HC Orders Feasibility Check on Fixing Time Limit for RTI Responses (23-09-2020)
- Implementation date for track and trace system for exports of drug formulations extended (23-09-2020)
- To get approval in India, vaccines must work in at least 50% cases (22-09-2020)
- Health ministry issues draft guidelines for development of vaccines (22-09-2020)
- China hikes prices of key drug ingredients (22-09-2020)
- IIT Madras develops magnesium alloy to fix bone fractures (22-09-2020)